Merit Medical Systems, Inc. $MMSI Shares Sold by Nomura Holdings Inc.

Nomura Holdings Inc. lowered its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 54.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 138,239 shares of the medical instruments supplier’s stock after selling 164,936 shares during the quarter. Nomura Holdings Inc.’s holdings in Merit Medical Systems were worth $12,923,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Evergreen Capital Management LLC increased its stake in shares of Merit Medical Systems by 2.4% during the first quarter. Evergreen Capital Management LLC now owns 4,616 shares of the medical instruments supplier’s stock worth $488,000 after acquiring an additional 108 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in Merit Medical Systems by 2.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,973 shares of the medical instruments supplier’s stock valued at $558,000 after purchasing an additional 131 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Merit Medical Systems by 55.6% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 375 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 134 shares during the period. Bryn Mawr Trust Advisors LLC raised its stake in shares of Merit Medical Systems by 7.2% during the 2nd quarter. Bryn Mawr Trust Advisors LLC now owns 2,225 shares of the medical instruments supplier’s stock worth $208,000 after buying an additional 149 shares in the last quarter. Finally, SageView Advisory Group LLC lifted its holdings in shares of Merit Medical Systems by 3.1% in the 1st quarter. SageView Advisory Group LLC now owns 5,065 shares of the medical instruments supplier’s stock valued at $535,000 after buying an additional 153 shares during the period. Institutional investors and hedge funds own 99.66% of the company’s stock.

Merit Medical Systems Stock Performance

NASDAQ:MMSI opened at $86.70 on Monday. The company has a current ratio of 4.28, a quick ratio of 2.86 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $5.14 billion, a P/E ratio of 44.46, a price-to-earnings-growth ratio of 2.77 and a beta of 0.62. The firm has a 50-day moving average price of $84.70 and a two-hundred day moving average price of $87.31. Merit Medical Systems, Inc. has a twelve month low of $78.12 and a twelve month high of $111.45.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Thursday, October 30th. The medical instruments supplier reported $0.92 EPS for the quarter, beating the consensus estimate of $0.82 by $0.10. Merit Medical Systems had a net margin of 8.02% and a return on equity of 14.27%. The business had revenue of $384.16 million for the quarter, compared to analyst estimates of $371.69 million. During the same period in the prior year, the business earned $0.86 earnings per share. The company’s quarterly revenue was up 13.0% on a year-over-year basis. Merit Medical Systems has set its FY 2025 guidance at 3.660-3.790 EPS. As a group, research analysts expect that Merit Medical Systems, Inc. will post 3.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on MMSI. Needham & Company LLC reaffirmed a “buy” rating and set a $108.00 price objective on shares of Merit Medical Systems in a report on Friday, October 31st. Wells Fargo & Company decreased their target price on shares of Merit Medical Systems from $103.00 to $95.00 and set an “overweight” rating on the stock in a research report on Friday, November 14th. Canaccord Genuity Group lowered their price target on shares of Merit Medical Systems from $104.00 to $93.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Barrington Research reiterated an “outperform” rating and issued a $106.00 price objective on shares of Merit Medical Systems in a research note on Friday, November 14th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Merit Medical Systems in a report on Monday, December 8th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $104.50.

Insiders Place Their Bets

In other news, Chairman Fred P. Lampropoulos sold 25,000 shares of the business’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $87.31, for a total value of $2,182,750.00. Following the completion of the transaction, the chairman directly owned 1,029,955 shares of the company’s stock, valued at $89,925,371.05. The trade was a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 60,000 shares of company stock worth $5,189,900 over the last ninety days. Company insiders own 3.70% of the company’s stock.

Merit Medical Systems Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.